LOS ANGELES–(Business Wire)– Goldberg Law PC , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Allergan plc (“Allergan” or the “Company”) (NYSE: AGN) and/or Actavis plc. Investors who purchased or otherwise acquired shares between February 25, 2014 and November 3, 2016 (the “Class Period”), are encouraged to contact the firm in advance of the January 3, 2017 lead plaintiff motion deadline .

If you are a shareholder who suffered a loss during the Class Period, click here to participate . In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com , or by email at [email protected] .

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The complaint alleges that during the Class Period, Allergan made false and/or misleading statements and/or failed to disclose that: Allergan and Actavis engaged in conduct that would result in a Department of Justice (“DOJ”) antitrust investigation; that the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against the Company by the end of 2016 for suspected price collusion; that Allergan and Actavis lacked effective internal controls; and that as a result of the above, Allergan’s and Actavis’ public statements were materially false and misleading at all relevant times. When this news was announced to the public, shares of Allergan fell in value, causing investors harm.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Please visit the source link below to read the entire article.